These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2574955)

  • 1. [Epidemiology of Parkinson disease].
    Domínguez Carmona M
    An R Acad Nac Med (Madr); 1989; 106(2):175-220. PubMed ID: 2574955
    [No Abstract]   [Full Text] [Related]  

  • 2. [Epidemiological assessment of levodopa consumption].
    de Pedro-Cuesta J; Cuadrado JI
    Rev Neurol; 2000 Dec 1-15; 31(11):1028-30. PubMed ID: 11190867
    [No Abstract]   [Full Text] [Related]  

  • 3. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent.
    Kline NS; Mason BT; Winick L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):838-43. PubMed ID: 4155670
    [No Abstract]   [Full Text] [Related]  

  • 4. [Parkinson disease].
    Soins Gerontol; 1999; (19):41-2. PubMed ID: 10745933
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacopsychiatry and iatrogenic parkinsonism].
    Pérez de Francisco C; Garnica Portillo R
    Neurol Neurocir Psiquiatr; 1978; 19(1):53-7. PubMed ID: 30054
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 7. Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges.
    Chen JJ
    Neurol Clin; 2004 Oct; 22(3 Suppl):S63-90. PubMed ID: 15501367
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Parkinson's disease in Spain.
    Grandas F; Kulisevsky J
    Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease].
    Criado-Alvarez JJ; Romo-Barrientos C; Martínez-Hernández J; González-Solana I
    Rev Neurol; 1998 Sep; 27(157):405-8. PubMed ID: 9774809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
    Martínez-Suárez MM; Blázquez-Menes B
    Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmaceutical care of Parkinson patients].
    Lennecke K
    Med Monatsschr Pharm; 2005 Jul; 28(7):228-36; quiz 237-8. PubMed ID: 16038120
    [No Abstract]   [Full Text] [Related]  

  • 12. [Parkinson's disease].
    Damier P
    Rev Prat; 2002 Jun; 52(11):1255-60. PubMed ID: 12148213
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective prevalence of pathologic gambling and medication association in Parkinson disease.
    Voon V; Hassan K; Zurowski M; Duff-Canning S; de Souza M; Fox S; Lang AE; Miyasaki J
    Neurology; 2006 Jun; 66(11):1750-2. PubMed ID: 16769956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992-2004).
    Osinaga EA; Inchaurregui LC; Ikobaltzeta IE; Alonso NB; Del Pozo JG
    Parkinsonism Relat Disord; 2007 Dec; 13(8):500-4. PubMed ID: 17532251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Parkinson's disease].
    Aubin L
    Soins; 1998 Apr; (624):XVII-XVIII. PubMed ID: 9633466
    [No Abstract]   [Full Text] [Related]  

  • 16. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological basis of therapeutics: dopamine receptors.
    Heikkila RE
    J Med Soc N J; 1984 Dec; 81(12):1084-6. PubMed ID: 6150999
    [No Abstract]   [Full Text] [Related]  

  • 18. [The prevalence of idiopathic Parkinson's disease].
    Giroud-Benítez JL
    Rev Neurol; 2001 Oct 1-15; 33(7):700. PubMed ID: 11784961
    [No Abstract]   [Full Text] [Related]  

  • 19. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 20. Psychosis in Parkinson's disease: how should we treat it?
    Shotbolt P; Samuel M; Anthony D
    Expert Rev Neurother; 2006 Sep; 6(9):1243-6. PubMed ID: 17009911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.